A study published in BMJ measured the prevalence, annual compensation, and beneficial stock ownership of directors from publicly traded healthcare companies who had academic affiliations.
Analysis of the prevalence, characters, and compensation of academicians who lend their expertise to the healthcare industry has identified ethical conflicts that could arise because of the dual role played by the experts.
Published in BMJ, the study conducted by researchers at the University of Pittsburgh measured the prevalence, annual compensation, and beneficial stock ownership of directors from publicly traded healthcare companies on the NASDAQ or Ney York Stock Exchange in 2013, who were simultaneously affiliated with academic institutions. Including 446 healthcare companies initially, the authors found 442 with publicly accessible disclosures on their board of directors, 180 of which had at least 1 academically affiliated directors. The 279 academically-affiliated directors were faculty in 85 geographically diverse non-profit academic institutions, 19 of the top 20 National Institutes of Health—funded medical schools.
Designations ranged from CEO or vice president of health systems and hospitals; university presidents, provosts, chancellors; medical school deans or presidents. The combined annual compensation earned by these individuals was nearly $55,000,000 (median individual compensation was $193,000). Combined stock ownership was 59,831,477 (median number was 50,699).
The authors based their research on the premise that secondary financial interests of individuals and companies can adversely influence primary patient care, research, and education goals. While professional societies have financial disclosures and restrictions in place, the focus has been on individuals who conduct industry-sponsored research; academics who serves on the board of directors of these for-profit companies have not received much scrutiny.
Their research, the authors conclude, showed that the compensation the directors receive for lending their expertise to the company often surpasses common academic clinical salaries. The resulting conflict of interest is beyond that of simple consulting relationships and needs a more detailed review by professional societies and academic institutions.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More